 THE DRIVING FORCE for new therapeutic products results from a practitioner’s need to treat patients, human or animal, for which there is no approved therapy or when patients are unresponsive to available therapies. In the proven approach of MLI, cohesive team efforts are focused on helping those patients.
New approaches of treatment evolve from an exhaustive study of the disease and the patient in order to discover a target that disrupts the disease process. From these studies arise candidate molecules for laboratory and clinical testing. If successful, these candidate products are then patented. Depending on the molecule and application, further evaluation is performed in larger, controlled FDA or USDA trials by Institute partners, or they are now ready for the nutraceutical supplement market.
A defining aspect of MLI and the Institute is that candidate therapeutic agents are naturally-occurring molecules, most of which have never been used therapeutically. Examples of such molecules that have been used successfully in formal government-authorized trials include the protein human chorionic gonadotropin (hCG) for benign prostatic hyperplasia and DNA for respiratory disorders.
Enhancing its ability to generate new therapeutic agents, the Institute does not have a large infrastructure. Instead, the Institute acts as a coordinator by initiating, facilitating, and organizing work with partners to realize its goals.
In addition to the summary provided for Current Projects, additional information on specific projects is available. You may call or write for a supplemental packet on our Diabetes Project, for example. The packet offers health and economic statistics for the disease as well as outlines the evidence gained from clinical use of the Institute’s therapeutic agent to treat diabetes.
Please see The Institute’s Focus for more information on our therapeutic agents.
| 
